Eric Singhi, MD, joins the Oncology Brothers to discuss adverse event management practices for patients with small cell lung cancer.
Anlotinib Combo Improves PFS/OS in Extensive-Stage Small Cell Lung Cancer
Data may support anlotinib/benmelstobart plus chemotherapy as a preferable frontline treatment option in extensive-stage small cell lung cancer.
Considering Dosing and AE Management Strategies With Tarlatamab in SCLC
Experts from Washington University in St. Louis discuss prior data and strategies for mitigating toxicities like CRS associated with tarlatamab in SCLC.
Lurbinectedin/Pembrolizumab Shows Significant Activity in Relapsed SCLC
Findings from the phase 1/2 LUPER trial support further assessment of lurbinectedin plus pembrolizumab in relapsed small cell lung cancer.
Updated ASCO Guidelines for Optimal Small Cell Lung Cancer Management
Practices are on the cusp of better understanding small cell lung cancer that in turn can help to advance treatment strategies for patients, says Gregory Peter Kalemkerian, MD.
Consolidative Thoracic Radiotherapy Improves Survival in ES-SCLC
Multivariate analysis showed consolidative thoracic radiotherapy improved OS/PFS vs control patients with ES-SCLC, with respective HRs of 0.53 and 0.90.
Tarlatamab Shows QOL, Symptom Benefits in Previously Treated SCLC
Patient-reported adverse effects associated with tarlatamab appeared to be generally mild in the phase 2 DeLLphi-301 trial.